Pharmacists should be aware of the new data and recommendations for targeted therapies, and how they relate to improvements in clinical efficacy and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies.

Clinicians need to know the nuances of using neoadjuvant and adjuvant targeted therapy and immunotherapy to improve outcomes for their patients with resected early-stage and locally advanced NSCLC.

Triple-negative breast cancer continues to be labeled with a poor prognosis secondary to the fact that it tends to be more aggressive and poses a greater risk of recurrence. Because it lacks the receptors that many drugs have been designed to target, the standard of practice remains chemotherapy. Therefore, research has been focused on trying to identify other therapeutic targets for which agents already exist or are currently being developed. Within recent years, PD-L1 inhibition is being studied in trials as a new avenue for treatment options in these patients. Current evidence demonstrates increased benefit when using these agents in combination with chemotherapy.

Since not all patients have access to a CLL specialist, the oncology pharmacist assumes an important role in understanding the best available clinical research, pairing that with the individual patient, and evaluating the outcomes to optimize patient care.

Clinicians are challenged to remain up-to-date about the treatment advances that will enable them to make informed decisions to optimize the clinical outcome of patients with relapsed/refractory disease.

The management of metastatic uveal melanoma still presents a major clinical challenge, and it is important for healthcare providers to be aware of the most current recommendations by the NCCN Panel.

This program will provide expert insights on the current recommendations of care for patients with breast cancer and include the latest clinical research updates to assist clinicians in formulating breast cancer management strategies.

In order to optimize overall patient outcomes, clinicians need to understand the evidence behind the current guidelines’ recommendations, the rationale for appropriate treatment selection, and the management of any treatment- or multiple myeloma-specific adverse events.

It is difficult for clinicians to stay current with the evolving treatment options for colorectal cancer, and they can benefit from education about these therapies.

Clinicians must be trained to use assessment tools and stay abreast of the trial data that are available to improve morbidity and mortality in those over 60 or 65. Pharmacists have the opportunity now to improve treatment outcomes and communication between patient and provider, so the patient receives the best care for their situation and goals.